Ceftriaxone versus ampicillin/sulbactam for the treatment of aspiration-associated pneumonia in adults-Reference-Cited by-同舟云学术

Ceftriaxone versus ampicillin/sulbactam for the treatment of aspiration-associated pneumonia in adults

Published:2019-11 Issue:15 Volume:8 Page:1275-1284
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Hasegawa Shinya¹,Shiraishi Atsushi²^ORCID,Yaegashi Makito³,Hosokawa Naoto⁴,Morimoto Konosuke⁵,Mori Takahiro⁶⁷⁸

Affiliation:

1. Department of Infectious Disease, Tokyo Metro Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-8524, Japan

2. Emergency & Trauma Center, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan

3. Department of General Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan

4. Department of Infectious Disease, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan

5. Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, 1-14 Bunkyo-cho, Nagasaki 852-8521, Japan

6. Department of General Internal Medicine, Eastern Chiba Medical Center, 3-6-2 Okayamadai, Togane, Chiba 283-8686, Japan

7. Department of General Medical Science, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

8. Research & Development Center for Health Services, Faculty of Medicine, University of Tsukuba, 1-1-1 Tenno-dai, Tsukuba, Ibaraki 305-8575, Japan

Abstract

Aim: To compare hospital mortality in patients with aspiration-associated pneumonia treated with ceftriaxone (CTRX) and in those treated with ampicillin/sulbactam (ABPC/SBT). Methods: From a Japanese multicentre observational study cohort of patients with pneumonia, those diagnosed with pneumonia and having at least one aspiration-related risk factor were selected. Propensity score-matching analysis was used to balance baseline characteristics of the participants and compare hospital mortality of patients treated with CTRX and those treated with ABPC/SBT. Results: Hospital mortality did not significantly differ between patients treated with CTRX and those treated with ABPC/SBT (6.6 vs 10.7%, risk difference -4.0, 95% CI [-9.4, 1.3]; p = 0.143). Conclusion: Further studies are needed to compare CTRX and ABPC/SBT treatments in patients with aspiration-associated pneumonia.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2019-0041

Reference38 articles.

1. WHO. The top 10 causes of death (2019). https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

2. Aspiration Pneumonitis and Aspiration Pneumonia

3. Differences in the Features of Aspiration Pneumonia According to Site of Acquisition: Community or Continuing Care Facility

4. Mortality, morbidity, and disease severity of patients with aspiration pneumonia

5. Risk Factors for Aspiration Pneumonia in Frail Older People: A Systematic Literature Review

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aspiration Pneumonia;Seminars in Respiratory and Critical Care Medicine;2024-01-11

2. Cost-minimization analysis of pneumonia treatment in Indonesia;Pharmacia;2023-06-15

3. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia;Intensive Care Medicine;2023-04-04

4. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia;European Respiratory Journal;2023-04

5. The Clinical Significance of Anaerobic Coverage in the Antibiotic Treatment of Aspiration Pneumonia: A Systematic Review and Meta-Analysis;Journal of Clinical Medicine;2023-03-02